Landmark CRISPR approval; Why don't investors like Verve’s base editing data?; Janet Woodcock to retire; Late Friday IPO filing; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
This week, we showcase Endpoints’ on-the-ground coverage with dispatches from the AHA meeting in Philadelphia and the Jefferies conference in London. But don’t miss the string of new approvals, deals, financing and departures, either.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.